Early Results With Poziotinib in EGFR-Mutant Lung Cancer
“These data are remarkable,” announced John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, in a press release regarding the early promising results of poziotinib treatment in patients with epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) and exon 20 mutations. Dr. Heymach coauthored this ongoing phase II study, which was presented at the 2017 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (Abstract OA 12.01) in Yokohama, Japan.
“These patients currently have a poor prognosis, single-digit response rate on first generation tyrosine kinase inhibitors, and a progression-free survival of about 2 months,” noted Dr. Heymach. “What is truly noteworthy is that all study patients who received poziotinib and have reached their first scan have seen some level of tumor shrinkage.”
Of the eight platinum-refractory patients with EGFR exon 20 mutations who are enrolled, two have reached the first interval-imaging time point and exhibited partial response. One patient had a partial response after 3 weeks of treatment. Reported toxicities, including rash, diarrhea, paronychia, and mucositis, seemed to be consistent with previous poziotinib treatments and other tyrosine kinase inhibitors.